Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (Domen Ribnikar) .

1 - 10 / 10
First pagePrevious page1Next pageLast page
1.
Sistemsko zdravljenje HR+ HER2-negativnega raka dojk
Domen Ribnikar, 2023, published professional conference contribution

Keywords: rak dojk, sistemsko zdravljenje, kemoterapija
Published in DiRROS: 08.01.2024; Views: 110; Downloads: 32
.pdf Full text (235,29 KB)

2.
Učinkovitost in varnost alpeliziba pri zdravljenju HR+, HER2-, PIK3CA-mutiranega razsejanega raka dojk : raziskava iz realnega sveta
Eva Godina, Domen Ribnikar, Simona Borštnar, 2022, published professional conference contribution abstract

Keywords: onkologija, rak dojke, kemoterapija
Published in DiRROS: 09.02.2023; Views: 295; Downloads: 73
.pdf Full text (60,60 KB)

3.
4.
Vpliv opustitve dopolnilne kemoterapije na preživetje bolnic z zgodnjim ER+/HER2+ rakom dojk
Valentina Jerič Horvat, Damjan Manevski, Barbara Gazić, Primož Drev, Domen Ribnikar, Erika Matos, Boštjan Šeruga, 2022, published professional conference contribution abstract

Keywords: onkologija, rak dojke, kemoterapija
Published in DiRROS: 27.01.2023; Views: 348; Downloads: 98
.pdf Full text (47,33 KB)

5.
Pljučna toksičnost pri sistemskem zdravljenju raka
Daša Bosilj, Dimitar Stefanovski, Domen Ribnikar, 2022, published scientific conference contribution

Abstract: Pljučna toksičnost se lahko pojavlja pri sistemskem zdravljenju s klasičnimi kemoterapevtiki, tarčnimi zdravili in imunoterapijo. Opisanih je več kliničnih sindromov pljučne toksičnosti, najpogosteje govorimo o intersticijskem pneumonitisu. Diagnoza je radiološka in izključitvena. V primeru pljučne toksičnosti je potrebna začasna ali trajna prekinitev zdravljenja, v hujših primerih je indicirano zdravljenje s kortikosteroidi.
Keywords: neželeni učinki, bolniki, sistemsko zdravljenje
Published in DiRROS: 17.01.2023; Views: 376; Downloads: 82
.pdf Full text (72,34 KB)

6.
BAP1-defficient breast cancer in a patient with BAP1 cancer syndrome
Ana Blatnik, Domen Ribnikar, Vita Šetrajčič Dragoš, Srdjan Novaković, Vida Stegel, Biljana Grčar-Kuzmanov, Nina Boc, Barbara Perić, Petra Škerl, Gašper Klančar, Mateja Krajc, 2022, original scientific article

Abstract: BAP1 cancer syndrome is a rare and highly penetrant hereditary cancer predisposition. Uveal melanoma, mesothelioma, renal cell carcinoma (RCC) and cutaneous melanoma are considered BAP1 cancer syndrome core cancers, whereas association with breast cancer has previously been suggested but not confirmed so far. In view of BAP1 immunomodulatory functions, BAP1 alterations could prove useful as possible biomarkers of response to immunotherapy in patients with BAP1-associated cancers. We present a case of a patient with BAP1 cancer syndrome who developed a metastatic breast cancer with loss of BAP1 demonstrated on immunohistochemistry. She carried a germline BAP1 likely pathogenic variant (c.898_899delAG p.(Arg300Glyfs*6)). In addition, tumor tissue sequencing identified a concurrent somatic variant in BAP1 (partial deletion of exon 12) and a low tumor mutational burden. As her triple negative tumor was shown to be PD-L1 positive, the patient was treated with combination of atezolizumab and nab-paclitaxel. She had a complete and sustained response to immunotherapy even after discontinuation of nab-paclitaxel. This case strengthens the evidence for including breast cancer in the BAP1 cancer syndrome tumor spectrum with implications for future cancer prevention programs. It also indicates immune checkpoint inhibitors might prove to be an effective treatment for BAP1-deficient breast cancer.
Keywords: BAP1, breast cancer, hereditary cancer syndromes, immunotherapy
Published in DiRROS: 19.09.2022; Views: 411; Downloads: 169
.pdf Full text (1,12 MB)

7.
Toksičnost stereotaktičnega obsevanja in sistemskega zdravljenja
Domen Ribnikar, 2020, published professional conference contribution

Keywords: stereotaktično obsevanje, radioterapija, toksičnost
Published in DiRROS: 14.04.2022; Views: 561; Downloads: 188
.pdf Full text (190,02 KB)

8.
Adjuvantna kemoterapija pri zgodnjem HR+ HER2-raku dojk - utvara
Domen Ribnikar, 2021, published scientific conference contribution

Keywords: obsevanje, radioterapija, onkološko zdravljenje
Published in DiRROS: 24.03.2022; Views: 471; Downloads: 231
.pdf Full text (335,76 KB)
This document has many files! More...

9.
Delitev in podtipi raka dojk
Domen Ribnikar, 2019, published professional conference contribution

Keywords: rak dojk, zdravljenje, onkološko zdravljenje
Published in DiRROS: 20.05.2020; Views: 1411; Downloads: 401
.pdf Full text (54,16 KB)

10.
Potek bolezni pri bolnicah s HER-2 pozitivnim rakom dojk
Domen Ribnikar, Špela Fink, Snježana Frković-Grazio, Hotimir Lešničar, Aleksander Sadikov, Tanja Čufer, 2008, original scientific article

Published in DiRROS: 31.08.2018; Views: 3027; Downloads: 715
.pdf Full text (230,67 KB)

Search done in 0.22 sec.
Back to top